Skip to content
Back to news

Adaptix and IBEX sign MOU to bring X-ray bone health assessment to the point-of-care

By Carla Taylor
17 Nov 26 • 3 min read
Medical imaging innovator Adaptix Ltd (Adaptix) has signed a Memorandum of Understanding (MOU) with IBEX Innovations Ltd (IBEX) to work together to integrate IBEX CorteX bone health software into its FDA 510(k) cleared and CE marked Ortho 3D X-ray Imaging System (Adaptix Ortho350) and provide patients with a pay-per-scan bone density report at the point of care (POC).

CorteX outputs the same recognised clinical biomarkers as DXA, with a low T-score at the wrist being an established indicator of elevated fracture risk and general bone loss, a key concern, particularly for women approaching the menopause. CorteX is CE-marked and is FDA 510(k) submission pending and not yet available for sale, distribution, or commercial use in the US.

The Adaptix Ortho350 is a cutting-edge, portable Digital Tomosynthesis (DT) system designed to provide high-resolution, low-dose 3D imaging for musculoskeletal diagnostics at the POC. This revolutionary system addresses the limitations of traditional 2D X-ray imaging while offering a more accessible alternative to full CT scans.

By integrating the CorteX pay-per-scan bone health software into the Adaptix Ortho350 portable 3D X-ray imaging platform, the two companies aim to make bone density assessment widely available at the POC. Preliminary surveys indicated this would be strongly welcomed by patients if offered on a cash-pay basis alongside other routine clinical assessments.

Stuart Gall, CEO of Adaptix, said:
“We are excited to be taking this first step with IBEX and working with them to bring their excellent bone density test to market on the Ortho350 imaging platform. We have asked them to join our exhibition stand at RSNA 2026 in Chicago and would welcome any imaging centres, hospitals or interested OEMs to visit us on Stand 3159, South Hall, Level 3.”

Note: The integrated CorteX software is FDA 510(k) submission pending and is not available for commercial distribution or sale in the United States.

Dr Paul Scott, CEO of IBEX, said:
“Together we are bringing bone health assessment to the physician’s desktop. This is transformational for patients who often only become aware of a problem once a fracture has occurred. Making bone health assessment fast, easy and widely accessible is the missing ingredient to support clinicians in stopping osteoporosis in its tracks.”

Regulatory status
The Adaptix Ortho350 is CE marked and FDA 510(k) cleared for sale in the US.
CorteX is CE marked but is FDA 510(k) submission pending and not yet available for sale, distribution, or commercial use in the US.